Vaccine acquisitions could pave the way for Bavarian Nordic's 2025 ambitions

The biotech company is training its sights on becoming one of the world’s biggest vaccine companies in 2025, when it expects a billion-dollar revenue. To get to this point, Bavarian Nordic has formulated a two-pronged approach.

Photo: Bavarian Nordic / PR

A lot is going on at Bavarian Nordic: the transfer of Glaxosmithkline’s vaccines Rabipur and Encepur, three ongoing clinical cancer studies, the development of RSV and Covid-19 vaccines, an expansion of production facilities in Denmark and a liquid-frozen formulation of the company’s smallpox vaccine.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs